145743-85-7

Basic information

• Product Name: Pyridine, 3-bromo-5-(bromomethyl)- (9CI)
• Synonyms: Pyridine, 3-bromo-5-(bromomethyl)- (9CI);Pyridine, 3-broMo-5-(broMoMethyl)-
• CAS NO: 145743-85-7
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 250.9186
• Product Categories: PYRIDINE
• Mol File: 145743-85-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 277.312ºC at 760 mmHg
• Flash Point: 121.514ºC
• Appearance: /
• Density: 1.955g/cm3
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.613
• PKA: 1.97±0.20(Predicted)
• CAS DataBase Reference: Pyridine, 3-bromo-5-(bromomethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 3-bromo-5-(bromomethyl)- (9CI)(145743-85-7)
• EPA Substance Registry System: Pyridine, 3-bromo-5-(bromomethyl)- (9CI)(145743-85-7)

Safety Data

• Hazardous Substances Data: 145743-85-7(Hazardous Substances Data)

Usage

General Description

Pyridine, 3-bromo-5-(bromomethyl)- (9CI) is a chemical compound with the molecular formula C6H6Br2N. It is a derivative of pyridine, a six-membered heterocyclic ring with one nitrogen atom, and it contains two bromine atoms and a bromomethyl group. This chemical compound is commonly used in organic synthesis and pharmaceutical research. It is known for its reactivity and is often used as a building block in the synthesis of various organic compounds. Its unique structure and properties make it a valuable tool in the field of organic chemistry.

InChI:InChI=1/C6H5Br2N/c7-2-5-1-6(8)4-9-3-5/h1,3-4H,2H2

Upstream product

• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 584-08-7 potassium carbonate 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 

Downstream Products

• 1004794-08-4 tert-butyl 4-(((5-bromopyridin-3-yl)methoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 145829-58-9 2-[(5-bromo-3-pyridinyl)methyl]-5-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-methyl-3-pyrazolidinone hydrochloride 

Relevant articles and documents

Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker

Neuronal nitric oxide synthase (nNOS) is an important therapeutic target for the treatment of various neurodegenerative disorders. A major challenge in the design of nNOS inhibitors focuses on potency in humans and selectivity over other NOS isoforms. Here we report potent and selective human nNOS inhibitors based on the 2-aminopyridine scaffold with a central pyridine linker. Compound 14j, the most promising inhibitor in this study, exhibits excellent potency for rat nNOS (Ki = 16 nM) with 828-fold n/e and 118-fold n/i selectivity with a Ki value of 13 nM against human nNOS with 1761-fold human n/e selectivity. Compound 14j also displayed good metabolic stability in human liver microsomes, low plasma protein binding, and minimal binding to cytochromes P450 (CYPs), although it had little to no Caco-2 permeability.

ALDOSTERONE SYNTHASE INHIBITORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.